| Drug General Information |
| Drug ID |
D06HRY
|
| Former ID |
DNC003939
|
| Drug Name |
SNAP-5089
|
| Drug Type |
Small molecular drug
|
| Indication |
Heart arrhythmia [ICD10:I47-I49]
|
Terminated |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C36H40N4O5
|
| InChI |
InChI=1S/C36H40N4O5/c1-25-31(33(32(26(2)38-25)35(42)45-3)27-15-17-30(18-16-27)40(43)44)34(41)37-21-10-22-39-23-19-36(20-24-39,28-11-6-4-7-12-28)29-13-8-5-9-14-29/h4-9,11-18,33,38H,10,19-24H2,1-3H3,(H,37,41)/t33-/m1/s1
|
| InChIKey |
FIIXCJGBCCCOQQ-MGBGTMOVSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[4]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
| Voltage-dependent L-type calcium channel alpha-1D subunit |
Target Info |
Inhibitor |
[5]
|
| Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[4]
|
| Voltage-dependent L-type calcium channel subunit alpha-1C |
Target Info |
Inhibitor |
[3]
|
| Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[4]
|
| Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
AMPK signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04010:MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Cardiac muscle contraction
|
|
Circadian entrainment
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Carbohydrate digestion and absorption
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
Dilated cardiomyopathyhsa04020:Calcium signaling pathway
|
|
Salivary secretionhsa04010:MAPK signaling pathway
|
|
Long-term potentiation
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
Beta2 adrenergic receptor signaling pathway
|
|
Oxytocin receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion
|
|
NCAM1 interactions
|
|
Regulation of insulin secretionR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling eventsR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Endothelin Pathways
|
|
GPCR downstream signaling
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
|
Integration of energy metabolism
|
|
GPCR downstream signalingWP536:Calcium Regulation in the Cardiac Cell
|
|
Arrhythmogenic Right Ventricular Cardiomyopathy
|
|
Alzheimers Disease
|
|
NCAM signaling for neurite out-growth
|
|
Integration of energy metabolismWP58:Monoamine GPCRs
|
|
GPCRs, OtherWP536:Calcium Regulation in the Cardiac Cell
|
|
Nicotine Activity on Chromaffin CellsWP58:Monoamine GPCRs
|
|
Vitamin D Receptor Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 498). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006771) |
|---|
| REF 3 | Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.Design and synthesis of novel dihydropyridine alpha-1a antagonists. |
|---|
| REF 4 | J Med Chem. 1995 Sep 15;38(19):3681-716.Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. |
|---|
| REF 5 | J Med Chem. 1995 May 12;38(10):1579-81.Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. |
|---|
